Thumzup Media Corp. (NASDAQ: TZUP)

The QualityStocks Daily Newsletter would like to spotlight Thumzup Media Corp.(NASDAQ: TZUP).

Thumzup (NASDAQ: TZUP) , an emerging player in social media branding and programmatic marketing, reported that company insiders acquired approximately $60,381 in common stock during the March 2025 trading window, following $62,000 in purchases in Dec. 2024. Cumulatively, insiders have invested over $740,000 in the company since inception. Thumzup also repurchased about $216,000 worth of stock in the past three trading days under its $1 million buyback program, signaling continued confidence in its growth trajectory. The company recently surpassed 700 advertisers and maintains a CAGR above 200 percent.

To view the full press release, visit https://ibn.fm/dAvCn

Thumzup Media Corp. (NASDAQ: TZUP) is at the forefront of modernizing the social media branding and marketing industry with its unique platform designed to connect advertisers directly with everyday social media users. The company’s mission is to empower individuals by turning their authentic social media activity into a monetizable asset while providing brands with cost-effective and impactful advertising solutions.

Through its flagship Thumzup platform, the company offers a seamless system where users post about participating advertisers and receive cash payments via Venmo or PayPal. Thumzup recently announced plans to integrate bitcoin as an additional payment option, expanding accessibility for gig economy workers.

By prioritizing accessibility and transparency, Thumzup is redefining traditional marketing strategies with an inclusive, user-driven approach. It is leveraging its scalable technology to disrupt the status quo, offering a win-win ecosystem for advertisers and users alike.

The company is headquartered in Los Angeles, California.

Products

Thumzup’s key offering, the Thumzup platform, features two integrated components: a sophisticated advertiser dashboard and an intuitive consumer-facing app. The advertiser dashboard provides companies with tools to design, manage, and analyze campaigns.

On the consumer side, the Thumzup app allows users to participate in campaigns by posting approved content to their social media accounts. In exchange, users receive direct cash rewards.

Recent enhancements to the platform include the launch of video capabilities, enabling integration with Instagram Reels. This update allows advertisers to tap into the growing popularity of short-form video content, broadening campaign possibilities.

The platform not only incentivizes users but also delivers authentic, relatable content for advertisers, bridging the gap between grassroots engagement and effective campaign management.

Market Opportunity

The global social media advertising market is projected to reach $219.8 billion in 2024, with an expected annual growth rate of 3.86%, resulting in a market volume of $255.8 billion by 2028, according to Statista. Thumzup targets the intersection of this growth with the rise of micro-influencers and everyday social media users, a segment that remains largely untapped in the advertising ecosystem.

In October 2024, Thumzup achieved 202% year-over-year growth in advertisers on its proprietary platform, demonstrating significant traction and scalability. With plans for further expansion in both advertiser partnerships and user engagement, the company is well-positioned to capitalize on the growing demand for authentic and trust-building marketing strategies. As Thumzup integrates innovative features like video support and continues its geographic expansion, it is poised to capture a larger share of the rapidly growing social media advertising market.

Leadership Team

Robert Steele, Founder and Chief Executive Officer of Thumzup, has over 25 years of experience as a technologist and entrepreneur. He has successfully launched multiple companies, including iBrite, a pioneer in mobile software development. Mr. Steele’s leadership and innovative vision drive Thumzup’s mission to democratize the social media marketing industry.

Robert Haag, Director of Thumzup, is the Managing Member of Westside Strategic Partners LLC and a Managing Director at IRTH Communications. With decades of experience in financial communications, investment, and corporate strategy, Mr. Haag provides critical guidance on strategic initiatives and business growth.

Dr. Joanna Massey, member of the company’s Board of Advisors, brings over 25 years of executive experience with Fortune 500 companies and startups to Thumzup. She has held senior roles in communications at Lions Gate Entertainment and CBS Corporation. Dr. Massey leverages her expertise to support Thumzup’s growth strategy.

Thumzup Media Corp. (NASDAQ: TZUP), closed Monday's trading session at $4.16, up 1.836%, on 216,692 volume. The average volume for the last 3 months is 112,110 and the stock's 52-week low/high is $2.02/$7.89.

Recent News

• Thumzup Media Corp. (NASDAQ: TZUP) - TechMediaBreaks - Thumzup Media Corp. (NASDAQ: TZUP) Reports Insider Stock Purchases and Accelerated Buybacks
• Thumzup Media Corp. (NASDAQ: TZUP) Boosts Shareholder Value with Share Buyback
• TechMediaBreaks - Thumzup Media Corp. (NASDAQ: TZUP) Repurchases $126,507 in Common Stock 

Software Effective Solutions Corp. (OTC: SFWJ)

The QualityStocks Daily Newsletter would like to spotlight Software Effective Solutions Corp. (OTC: SFWJ).

A proposal introduced by Sen. Colleen Burton that would ban delta-8 THC hemp products is being discussed by legislators in Florida. The measure, SB 438, would also restrict levels of delta-9 THC in hemp products to 50mg per package and 5mg per serving. This is in addition to limiting the amount of THC per can or bottle to no more than 5mg for hemp-infused beverages and prohibiting the sale of these drinks at premises not licensed to sell alcoholic drinks. This is the 3^rd year in a row Senator Burton is spearheading efforts to regulate hemp products, which have proliferated markets around the country since the crop was legalized with the passage of the 2018 Farm Bill. Last year, Gov. Ron DeSantis vetoed a similar proposal that had been approved by legislators, explaining that heavy regulatory burdens would've been imposed on small businesses. Following approval by the Agriculture Committee earlier this week, the measure has now been advanced to the Senate floor. Hemp companies like Software Effective Solutions Corp. (d/b/a MedCana) (OTC: SFWJ) operating around the country will be watching the push to regulate hemp products in Florida to see how their plans could be impacted.

Software Effective Solutions Corp. (d/b/a MedCana) (OTC: SFWJ) is a global infrastructure and holding company in the cannabis industry. MedCana currently has five companies focused on pharmaceutical cannabis production, as well a software company focused on managing processes for plant-to-patient operations. The recent acquisition of an irrigation and greenhouse technology company has rounded out MedCana’s portfolio of holdings.

MedCana’s focus is on developing clients and companies in Latin America, initially in Colombia, and partnerships with laboratories, research facilities and hospitals throughout the world. MedCana is building the technology, laboratories, growing facilities and scientific teams to provide premium pharmaceutical-grade cannabis extracts to the world.

MedCana’s goal is to be the world’s premier resource for pharmaceutical cannabis products. The company believes its advantage is its global view and reach. From initial cultivation to final product, MedCana aims to help partners produce pharmaceutical CBD and other extracts that will have no equal.

The company’s mission is to utilize its technology to partner with and develop companies that provide premium pharmaceutical-grade cannabis extracts with absolute integrity, sustainability and social responsibility. MedCana’s team of pharmaceutical scientists includes some of the most respected chemists in the world. They aim to ensure that the company’s customers and partners create premium cannabis extracts that meet the growing worldwide demand. MedCana’s software is designed to ensure traceability and quality from seed to finished product.

MedCana is headquartered in Austin, Texas, with offices in Colombia.

Production

MedCana announced in May 2023 the beginning of full-scale production of non-THC cannabis for export to Europe in response to high demand in that market. This expansion comes after the successful completion of full crop cycle testing and infrastructure development at production sites in Columbia.

The recent acquisition of the assets of Tokan Corp., a software company focused on creating an enterprise resource planning (ERP) platform for the cannabis industry, and Eko2O S.A.S., a greenhouse and irrigation engineering company, has positioned MedCana for explosive growth in the region.

As a MedCana subsidiary, Eko2O SA will increase the company’s revenue potential in Central and South America. The subsidiary specializes in the construction and distribution of greenhouses and sophisticated irrigation platforms. A positive outlook has resulted from the company’s expansion as it investigates new opportunities for greenhouse and irrigation system installations in Panama and Uruguay. These opportunities are expected to accelerate Eko2O’s development and strengthen its position as a top supplier of innovative agricultural solutions in cannabis and other sectors that are quickly moving to high technology agricultural production.

In addition, MedCana has started talks with the government in Argentina about possible incentives for beginning operations in that country as part of its ongoing worldwide development strategy. Support from the Argentinean government and the start of new operations there would greatly increase MedCana’s market share in Latin America and solidify the company’s position as the market leader in the cannabis industry.

Market Opportunity

According to a report by Grand View Research, a San Francisco-based market research and consulting company, the global cannabis extract market was valued at $3.5 billion in 2022 and is expected to expand at a CAGR of 20% from 2023 to 2030 to be worth more than $15 billion.

Growing demand for cannabis extracts, including oils and tinctures, and the increased legalization of marijuana for the treatment of different chronic ailments like arthritis, Alzheimer’s, anxiety and cancer are driving the expansion of the industry. The marijuana derivative industry is flourishing due to a greater understanding of its various medical benefits.

Management Team

Jose Gabriel Diaz is CEO of MedCana. He has successfully built, grown and sold multiple telecom companies. He was senior vice president of sales at IP Communications, a national high-speed data provider. He also founded Reallinx, a national data carrier later sold to GTT Communications. Additionally, he is currently president of the A.E.M. Business and Entrepreneurship Association in Austin, Texas.

Claudio Jiménez Cartagena, QF, Ph.D. is Chief Scientific Officer at MedCana. He joined MedCana after working with Sosteli Pharma as Technical Director and serving as a director consultant for the Corporation for Agricultural Industrial Development at the University of Antioquia in Colombia. Before that, he worked as the scientific director at the Institute of Food Science & Technology. He holds a bachelor’s degree in pharmaceutical chemistry, a master’s degree in basic biomedical sciences and a doctoral degree in Environmental Engineering from the University of Antioquia.

Julián Alberto Londoño Londoño, Ph.D., is Senior Vice President of Operations at MedCana. He previously served as general manager for the Corporation for Agricultural Industrial Development, and as Chief Scientific Officer at Sosteli Pharma in the Resource Management Department. He has developed multiple U.S. patents, and recently served as senior advisor to the Secretariat of Agriculture Development for the Government of Antioquia. He holds a doctorate in Chemical Sciences from the University of Antioquia.

Software Effective Solutions Corp. (OTC: SFWJ), closed Monday's trading session at $0.01, even for the day, on 53,000 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0071/$0.06.

Recent News

• Software Effective Solutions Corp. (OTC: SFWJ) - Senate Panel in Florida Starts Discussing Bill Restricting Hemp Products
• California Extends Prohibition of Hemp Products with THC
• Poll Finds More Consumers Want to Use Hemp Delivery Services

Clene Inc. (NASDAQ: CLNN)

The QualityStocks Daily Newsletter would like to spotlight Clene Inc. (NASDAQ: CLNN).

Clene (NASDAQ: CLNN) , a late clinical-stage biopharmaceutical company, reported a full-year 2024 net loss of $39.4 million, or $5.67 per share, compared to a loss of $49.5 million in 2023. Revenue remained limited, but Clene highlighted regulatory progress and survival data supporting CNM-Au8, its gold nanocrystal suspension for ALS. The company expects to meet with the FDA in Q2 2025 to finalize analysis plans for biomarker data, with a potential accelerated NDA submission in the second half of 2025. Clene ended the year with $12.2 million in cash and expects to begin enrollment for its confirmatory Phase 3 RESTORE-ALS trial in mid-2025.

To view the full press release, visit https://ibn.fm/uA4y1

Clene Inc. (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).

Its lead drug candidate is CNM-Au8®, an oral suspension developed to restore neuronal health and function by increasing energy production and utilization by driving critical cellular energy producing reactions that enable neuroprotection and remyelination to increase neuronal and glial resilience to disease-relevant stressors. CNM-Au8 is being studied in various clinical trials, including the Harvard/MGH Healey ALS Platform clinical trial for patients with ALS; RESCUE-ALS, a completed proof-of-concept clinical trial in patients with early symptomatic ALS; the REPAIR trials, completed target engagement clinical trials showing brain energy metabolite change with CNM-Au8; and a completed MS clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing MS. The company also has a nanotherapeutic platform of drug discovery.

CNM-Au8

CNM-Au8, Clene’s lead asset, is a highly concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. Multiple pathogenic insults contribute to neuronal death. Mitochondrial dysfunction and NAD+ decline is a common final pathway in neurodegeneration, with NAD+ as a critical determinant of cell survival and function. CNM-Au8’s catalytic mechanisms target the energetic deficits, oxidative stress and accumulation of misfolded proteins that are common to many neurodegenerative diseases.

The unique catalytic mechanism of action of CNM-Au8 is hypothesized to act as a neuroprotective and remyelinating therapy in neurodegenerative disease states in order to: (1) drive, support and maintain beneficial metabolic and energetic cellular reactions within diseased, stressed and/or damaged cells, (2) directly catalyze the reduction of harmful, reactive oxygen species (“ROS”) and (3) promote protein homeostasis via activation of the heat shock factor-1 pathway, recognized to dampen the cytotoxicity caused by misfolded and denatured proteins, which are known to occur ubiquitously in neurodegenerative diseases.

CNM-Au8 is used in combination with other agents, has no known drug-drug interactions, and is designed to improve function and survival. The clinical effects of both function and survival were seen in its clinical ALS trials, as earlier announced.

More than 500 estimated years of collective exposure across ALS, MS, and Parkinson’s disease participants in CNM-Au8 clinical trials and Expanded Access Protocol (compassionate use) programs have been recorded without any observed safety signals.

CNM-Au8 is a federally registered trademark of Clene Inc. Clene, based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland, began in 2013.

Market Opportunity

ALS is the most prevalent adult-onset progressive motor neuron disease, affecting approximately 30,000 people in the U.S. and an estimated 500,000 people worldwide, with a life expectancy of typically three to five years. Clene estimates that global ALS treatment sales will be greater than $1 billion annually within the coming few years. Additional treatments affecting daily function and survival remain the market need.

Additionally, there are more than 2 million MS patients globally, and Clene estimates the market size to be worth more than $23 billion annually. While the MS community has been successful at limiting relapses, non-relapsing MS patients continue to clinically deteriorate even while receiving effective immunomodulatory disease-modifying therapies (“DMTs”). A critical unmet medical need remains for therapeutic interventions that protect neuronal function and myelin health independent of immunomodulation to address progression independent of relapse activity.

Management Team

Robert Etherington is President, Director and CEO of Clene. He has more than 30 years of sales, marketing and leadership experience in the pharmaceutical industry. Prior to joining Clene, he worked at Actelion Pharmaceuticals, the largest biopharma company in the European Union prior to its acquisition by Johnson & Johnson in 2017, where he led that company’s U.S. commercial operations. He began his pharmaceutical sales and marketing career at Parke-Davis, a division of Pfizer, where he rose to the position of Team Leader overseeing the drug Lipitor.

Mark Mortenson is Chief Science Officer at Clene. He is co-inventor of the technology platform developed to produce the company’s therapeutics. He is the inventor or co-inventor on 32 other U.S. patents and hundreds of corresponding international patents. He is a former chief patent counsel responsible for 5,500 U.S. and international patents and patent applications. He holds bachelor’s degrees in physics and ceramic engineering from Alfred University, a master’s degree in materials science from Penn State University and a J.D. from George Washington University.

Benjamin Greenberg, M.D., MHS, FAAN, is Head of Medical at Clene. He is an internationally recognized expert in disorders of the central nervous system. He is currently professor of neurology and Vice Chair of Clinical and Translational Research in the department of Neurology at University of Texas Southwestern Medical Center in Dallas. He holds a bachelor’s degree from Johns Hopkins, a master’s degree in molecular microbiology and immunology from the Johns Hopkins School of Public Health and graduated from Baylor College of Medicine. He served residency in neurology at The Johns Hopkins Hospital.

Morgan R. Brown is CFO at Clene. He has more than 30 years of finance and accounting experience, with 23 years at biotech, pharmaceutical and medical device companies. He has served in similar roles at Lipocine Inc., Innovus Pharmaceuticals, World Heart Corp., Lifetree Clinical Research and NPS Pharmaceuticals Inc. He previously worked at accounting firm KPMG. He is a CPA with a bachelor’s degree in accounting from Utah State University and an M.S. in business administration from the University of Utah.

Clene Inc. (NASDAQ: CLNN), closed Monday's trading session at $3.92, off by 5.314%, on 112 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $3.8181/$9.2.

Recent News

• Clene Inc. (NASDAQ: CLNN) - BioMedNewsBreaks - Clene Inc. (NASDAQ: CLNN) Plans 2025 NDA Submission Following Positive ALS Trial Data 
• BioMedNewsBreaks - Clene Inc. (NASDAQ: CLNN) Unveils Progress on CNM-Au8(R), Eyes Potential Fast-Track FDA Approval
• Clene Inc.'s (NASDAQ: CLNN) CNM-Au8(R) Delivers Significant Survival Benefits in New Analyses of Healey ALS Platform Trial Data

Newton Golf Company Inc. (NASDAQ: NWTG)

The QualityStocks Daily Newsletter would like to spotlight Newton Golf Company Inc. (NASDAQ: NWTG).

The global golf equipment market is estimated at $18.34 billion in 2024 and forecasted to reach $29.3 billion by 2034.

The company's recent name change "marks a new chapter in our company's evolution as we push the boundaries of performance in golf equipment," says CEO.

Newton's advanced physics-driven designs are setting new standards in golf technology, from high-performance shafts to next-generation putters.

The global golf equipment market is experiencing significant growth, driven by increasing participation and technological advancements. This upward trend presents substantial opportunities for companies operating within the golf-equipment sector, such as Newton Golf Company (NASDAQ: NWTG) , a technology-forward golf equipment manufacturer committed to enhancing player performance through innovative design.

Newton Golf Company Inc. (NASDAQ: NWTG), a Sacks Parente Company, is a technology-forward golf equipment manufacturer committed to enhancing player performance through innovative design. Since its founding in 2018, the company has developed a growing portfolio of premium golf products, including putters, golf shafts, grips, and related accessories. Its proprietary advancements include the First Vernier Acuity putter, patented Ultra-Low Balance Point (ULBP) technology, weight-forward Center-of-Gravity (CG) design, and ultra-light carbon fiber putter shafts.

As part of its commitment to growth in golf shaft technologies, the company expanded its manufacturing operations in April 2022, opening a dedicated facility in St. Joseph, Missouri. This move reinforced its goal of maintaining high-quality production standards while manufacturing and assembling substantially all of its products in the United States. In addition to golf clubs and accessories, Newton Golf Company is exploring expansion into golf apparel and other product categories.

The company sells its products through multiple channels, including resellers, its direct-to-consumer website, Club Champion retail stores, and distributors in the U.S., Japan, and South Korea. Future expansion may include growth through mergers, acquisitions, or the development of complementary product lines.

Newton Golf Company is headquartered in Camarillo, California.

Products

Newton Golf Company is focused on delivering high-performance golf equipment with a strong emphasis on precision engineering and cutting-edge materials. The company’s key product lines include:

• Newton Motion Golf Shafts: Launched in November 2023, these shafts are engineered with proprietary flex profiles designed for greater distance, reduced dispersion, and optimized performance across swing speeds. The company’s DOT system eliminates traditional shaft flex definitions, making it accessible to all golfers.
• Gravity Putters: Introduced in October 2024, these putters incorporate patented Ultra-Low Balance Point (ULBP) technology to improve stroke consistency and tighten putt dispersion. Manufactured in the U.S., they feature premium materials such as steel, aluminum, titanium alloys, and patented magnesium face plate technology.
• Golf Grips & Accessories: The company continues to innovate in this category, providing golfers with performance-enhancing grips and accessories to complement their clubs.

All Newton Golf Company products are manufactured with strict quality control standards to ensure precision and reliability, reinforcing the brand’s reputation for premium performance.

Market Opportunity

The global golf equipment market was valued at approximately $8 billion in 2022, with the U.S. market accounting for $2.9 billion. The golf club segment dominated the industry, representing 45.7% of total market share. Increasing participation in golf, particularly among younger players and women, is driving demand for high-quality, customizable golf equipment.

Key industry trends supporting growth include:

• The increasing popularity of premium, high-performance golf equipment among both professionals and amateurs.
• A shift toward customization, as golfers seek tailored products that enhance performance.
• A growing interest in golf from younger demographics, with amateur and collegiate golfers being particularly receptive to innovation.

Newton Golf Company’s emphasis on U.S.-based manufacturing provides it with a competitive edge in terms of supply chain efficiency, quality control, and sustainability, further strengthening its position in the market.

Leadership Team

Dr. Greg Campbell, Executive Chairman and Chief Executive Officer, brings nearly 40 years of experience in emerging technologies, product development, and public company leadership. He currently serves as CEO of V-Grid Energy Systems, a California-based company focused on converting agricultural waste into renewable electricity and bio-carbon. He has successfully taken two companies public and previously managed a $1.2 billion P&L as SVP & GM at Lam Research. Campbell holds a Ph.D. in Electrical and Electronics Engineering from UCLA and a BA/MA in Engineering from Cambridge University.

Ryan Stearns, Chief Financial Officer, was appointed in 2024 and oversees financial planning and corporate strategy. He brings expertise in scaling businesses and optimizing financial performance to support the company’s growth.

Newton Golf Company Inc. (NASDAQ: NWTG), closed Monday's trading session at $1.73, off by 6.4865%, on 35,861 volume. The average volume for the last 3 months is 1,563,246 and the stock's 52-week low/high is $1.7/$195.

Recent News

• Newton Golf Company Inc. (NASDAQ: NWTG) - Newton Golf Company (NASDAQ: NWTG) 'Pioneering New Era' in Growing Golf Equipment Market
• InvestorNewsBreaks - Newton Golf Company Inc. (NASDAQ: NWTG) Launches New Investor Relations Website to Enhance Transparency 
• Newton Golf Company (NASDAQ: SPGC) Invigorates Future of Golf with Innovative Equipment, Customer Engagement

Brera Holdings PLC (NASDAQ: BREA)

The QualityStocks Daily Newsletter would like to spotlight Brera Holdings PLC(NASDAQ: BREA).

Brera Holdings (NASDAQ: BREA) , an Ireland-based international holding company focused on multi-club ownership, spotlighted the Juve Stabia Academy for its role in developing elite football talent in the Naples Metropolitan Area. The investment reflects Brera's strategy to support grassroots football and create a global network of academies. Juve Stabia has a history of producing top-tier talent, including Luigi Vitale and Antonio Donnarumma, and aligns with Brera's mission to strengthen football ecosystems and expand pathways for emerging players worldwide.

To view the full press release, visit https://ibn.fm/35S9L

Brera Holdings PLC (NASDAQ: BREA) is an Ireland-based, international holding company focused on expanding its global portfolio of men’s and women’s sports clubs through a multi-club ownership approach. The company capitalizes on opportunities to earn tournament prizes, secure sponsorships, collect transfer fees, provide professional sports consulting services, and enhance the valuation of its clubs.

Brera Holdings builds on the legacy of Brera FC, an international football club (referred to as soccer in the U.S.), that it acquired in July 2022. Established in 2000 and based in Milan, Italy, Brera FC has distinguished itself by cultivating an alternative football legacy. In October 2024, the Internet Marketing Association awarded Brera FC with the Social Impact Through Soccer accolade at its IMPACT 5050 Conference, recognizing the club’s global perspective and positive contributions to society.

The company’s growth strategy focuses on unlocking value from undervalued sports clubs and talent, driving innovation, and generating socially impactful outcomes. Brera Holdings is actively expanding its Global Sports Group, acquiring professional football and other sports clubs in emerging markets such as Africa, Asia, and Europe.

By targeting top-division teams in less mainstream markets, Brera Holdings aims to strengthen its competitive position in regional tournaments, including those organized by the Union of European Football Associations (UEFA). These acquisitions are expected to enhance sponsorship revenues and create new growth opportunities.

Leveraging its expertise in capital raising and revenue generation, Brera Holdings also anticipates growing demand for its consulting services, providing advisory support to sports clubs, associations, investors, and others. Brera Holdings is headquartered in Dublin, Ireland, with additional offices in Milan, Italy.

Sporting Assets

Brera Holdings continues to grow its global sports portfolio with a series of strategic acquisitions and innovations, including the FENIX Trophy Tournament, a pan-European, non-professional football competition. Launched in September 2021 and organized by Brera FC, the tournament has been recognized by UEFA and described by BBC Sport as “the Champions League for amateurs.” In 2023, Brera FC hosted the tournament’s finals at Milan’s iconic San Siro Stadium.

In March 2023, Brera Holdings expanded into Africa by establishing Brera Tchumene FC in Mozambique. Starting in the country’s Second Division League, the team quickly earned promotion to Moçambola, Mozambique’s First Division League, by November 2023.

In April 2023, Brera Holdings further strengthened its European presence by acquiring a 90% stake in Fudbalski Klub Akademija Pandev, a first-division football team in North Macedonia. This acquisition provides access to two major UEFA competitions, solidifying the company’s position in European football.

Brera Holdings’ reach extends beyond football. In July 2023, it acquired majority ownership of UYBA Volley, an Italian Serie A1 women’s professional volleyball team, demonstrating its commitment to diversifying within top-tier sports.

In September 2023, Brera Holdings entered the Mongolian football market by acquiring Bayanzurkh Sporting Ilch FC, a Mongolian National Premier League team. For the 2024 season, the club was rebranded as Brera Ilch FC, further expanding Brera’s global footprint.

In January 2024, Brera Holdings initiated a proactive search for an Italian Serie B football club, aligning with its goal of bringing multi-club ownership opportunities to mass investors through its Nasdaq-listed shares.

In February 2024, the Brera Holdings Advisory Board was established with MLS founder and World Cup director Alan Rothenberg, luxury lifestyle executive Massimo Ferragamo, sports business leaders Paul Tosetti and Marshall Geller, and Italian football icon Giuseppe Rossi.

In June 2024, the North Macedonian women’s football club Tiverija Strumica officially became part of the Brera family with the establishment of a joint-stock company controlled by Brera Holdings called Women’s Football Club Tiverija Brera AD Strumica (“Brera Tiverija”). Brera Tiverija is now a wholly-owned subsidiary of Brera Strumica FC.

In September 2024 Brera announced that it signed an exclusive letter of intent to acquire an Italian Serie B club (the “LOI” and the “Club”). According to a CFA report published in June 2024, this expected strategic transaction, for an estimated purchase price of $21.6 million, would add first-year annual revenue of $10.8 million to Brera, and that revenue would likely increase by 25% each year for the next three years. The company’s capital valuation, projected the report, would also experience significant appreciation during this period.

In October 2024, Brera was recognized with the 2024 Social Impact Through Soccer Award at IMPACT 5050, an annual event honoring leaders and innovators who significantly impact their industries and communities. This is the second time Brera has won the award.

Market Opportunity

A report from IMARC Group, a global management consulting firm, reveals that the international football market generated approximately $3.3 billion in revenue in 2023, with projections to grow to $4.6 billion by 2032, reflecting a compound annual growth rate (CAGR) of 3.6%. Key drivers behind this growth include advancements in digitization, increasing sponsorship and partnership deals between brands and clubs, the rising interest in women’s professional soccer leagues, and the expansion of the e-sports and gaming sector.

In particular, Serie B Italian football clubs seem to present exceptionally attractive investment opportunities. As of September 2024, more than half of these clubs had appreciated between 80-100% in total market value, post-purchase.

As the world’s most-watched and most-played sport, soccer drives significant demand for football-related products and services, contributing to market growth. Broadcasting rights, sponsorships, and endorsement deals are also major revenue sources for clubs and organizations, with an expanding global fanbase generating new opportunities for financial growth, according to the report.

Management Team

With extensive experience in leadership and finance, Daniel McClory currently serves as the Executive Chairman and Director of Brera Holdings, PLC. He co-founded and held the position of Chief Executive Officer at Boustead & Company Limited, and previously served as the Managing Director, Head of Equity Capital Markets, and Head of China at Boustead Securities, LLC. Mr. McClory’s governance experience includes being a Board Director for USA Track & Field and a member of the Eastern Michigan University Champions Advisory Board. Mr. McClory’s expertise encompasses founding and financing equity capital markets, as well as navigating merger and acquisition transactions and initial public offerings. He holds a BS and MS from Eastern Michigan University, where he also received an honorary Doctor of Public Service. In addition to his professional qualifications, he is fluent in both English and Italian.

Pierre Galoppi serves as the CEO, Interim CFO, and director of Brera Holdings. With over 30 years of experience in strategic business and financial services, his career spans a variety of industries, including natural resources, aviation, cybersecurity, telecommunications, tourism, and international marketing. He has worked extensively across Latin America, the Caribbean, Canada, Europe, and the United States. Mr. Galoppi holds dual citizenship in Canada and Italy and is fluent in English, Spanish, Portuguese, Italian, and French. He earned a Bachelor of Commerce degree and an MBA from Concordia University in Montreal.

Maria Xing serves as the Head of Investments and Corporate Development. She is an executive who has specialized in MCO football (soccer) group investments for 777 Partners, where she was involved in sourcing, direct negotiations, due diligence, and closing deals, including acquiring a controlling stake in Brazilian Serie A football club, Vasco da Gama, and investing in Australian Premier League (“A-League”) side, Melbourne Victory FC. She also played a role in other professional sports franchise portfolio management, including topflight professional football clubs in Italy, France, Germany, and Belgium. Her background is in private equity, investment banking, and finance, with prior experience at The Raine Group, Credit Suisse, and EY (Ernst & Young), as well as previous sports industry experience at Liverpool Football Club in international business development. Ms. Xing earned an MBA from the Wharton School of the University of Pennsylvania and a B.S. from the New York University, Stern School of Business.

Brera Holdings PLC (NASDAQ: BREA), closed Monday's trading session at $0.7, off by 0.3558719%, on 11,160 volume. The average volume for the last 3 months is 3,526,445 and the stock's 52-week low/high is $0.4999/$1.95.

Recent News

• Brera Holdings PLC (NASDAQ: BREA) - InvestorNewsBreaks - Brera Holdings PLC (NASDAQ: BREA) Highlights Juve Stabia Academy as Key Youth Football Investment
• Brera Holdings PLC (NASDAQ: BREA) Expands Commitment to Women's Football and Multi-Club Ownership ('MCO') Model
• Brera Holdings PLC (NASDAQ: BREA) Bolsters Advisory Board with the Addition of Famed Global Economist Dr. Arthur B. Laffer

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP)

The QualityStocks Daily Newsletter would like to spotlight Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP).

Tonix Pharmaceuticals (NASDAQ: TNXP) , a biopharmaceutical company with marketed products and a robust development pipeline, announced that the FDA will not require an Advisory Committee meeting to evaluate its New Drug Application for TNX-102 SL, a potential new treatment for fibromyalgia. If approved, TNX-102 SL would be the first new fibromyalgia therapy in 15 years. The drug, which previously received Fast Track designation, could launch in the fourth quarter of 2025. TNX-102 SL targets central sensitization and aims to address widespread dissatisfaction with current treatments.

To view the full press release, visit https://ibn.fm/qFX0c

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) is a fully-integrated biopharmaceutical company dedicated to developing, licensing, and commercializing innovative therapeutics aimed at treating and preventing human diseases and alleviating suffering. The company’s development portfolio is primarily focused on central nervous system (CNS) disorders, with its lead product candidate, TNX-102 SL, showing significant promise for the management of fibromyalgia. With two successful Phase 3 studies completed, Tonix is preparing to submit a New Drug Application (NDA) to the FDA in the second half of 2024 for TNX-102 SL, which has also been granted Fast Track designation. In addition to fibromyalgia, TNX-102 SL is being developed to treat acute stress reactions, further broadening its therapeutic potential.

Tonix’s CNS portfolio also includes TNX-1300, a biologic designed to treat cocaine intoxication, which has been granted Breakthrough Therapy designation by the FDA. This designation underscores the urgency and significance of developing an effective treatment for cocaine intoxication, a critical need in the healthcare system. Beyond CNS disorders, Tonix is expanding its immunology portfolio with the development of TNX-1500, a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154). TNX-1500 is being developed for the prevention of allograft rejection and the treatment of autoimmune diseases, highlighting Tonix’s commitment to addressing complex and challenging medical conditions.

In addition to its robust pipeline, Tonix has an established commercial presence through its subsidiary, Tonix Medicines, which markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg for the treatment of acute migraine in adults. The company’s diverse portfolio, spanning CNS disorders, immunology, rare diseases, and infectious diseases, positions Tonix as a leader in biopharmaceutical innovation, with a strong focus on developing therapies that address unmet medical needs and improve patient outcomes.

TNX-102 SL

TNX-102 SL is a groundbreaking, non-opioid, non-addictive investigational drug developed by Tonix Pharmaceuticals for the management of fibromyalgia where patients suffer chronic musculoskeletal pain, sleep deprivation, fatigue and mood changes. This patented sublingual formulation of cyclobenzaprine hydrochloride has demonstrated remarkable efficacy in clinical trials, including the recent RESILIENT Phase 3 trial, where it achieved highly statistically significant results in reducing daily pain compared to placebo (p=0.00005). The drug also showed significant improvements in sleep quality, fatigue reduction, and overall fibromyalgia symptoms and function across all key secondary endpoints. With similar success in the earlier RELIEF Phase 3 trial, TNX-102 SL is positioned as a promising new treatment option for fibromyalgia, particularly given its favorable safety profile, where the most common side effect was mild and self-limiting tongue or mouth numbness.

Recently granted Fast Track Designation by the FDA, TNX-102 SL is on course for a New Drug Application (NDA) submission in the second half of 2024. This designation highlights the urgent need for new fibromyalgia treatments and underscores the drug’s potential to effectively address this challenging condition. With its strong clinical results and focus on improving multiple aspects of fibromyalgia, TNX-102 SL offers hope for patients seeking better management of their symptoms and represents a significant advancement in the treatment landscape for this debilitating disorder.

Market Opportunity

From an investment perspective, Tonix Pharmaceuticals is strategically positioned to capitalize on the growing demand for effective treatments in the central nervous system (CNS) disorder market, particularly within the fibromyalgia segment, which is estimated to affect up to 10 million people in the U.S. alone. With the potential approval of TNX-102 SL, Tonix could tap into a significant and underserved market, offering a non-opioid alternative for a condition that currently has limited treatment options. The recent positive results from the Phase 3 trials and the FDA’s Fast Track designation increase the likelihood of TNX-102 SL gaining market approval, which could significantly boost Tonix’s market share and revenue potential.

In addition to its lead candidate, Tonix’s diversified pipeline, which includes treatments for conditions such as cocaine intoxication and autoimmune diseases, broadens market opportunities and reduces single product dependency. The company’s established commercial presence with its migraine treatments, combined with the advancement of its CNS and immunology portfolios, positions Tonix to become a key player in the biopharmaceutical industry. As the company moves closer to potential product launches and reached new clinical milestones, it stands to attract substantial investor interest, offering significant upside potential as it addresses critical unmet needs across multiple therapeutic areas.

Leadership Team

Dr. Seth Lederman is the Co-Founder, CEO, and Chairman of Tonix Pharmaceuticals, bringing decades of experience in the biotechnology and pharmaceutical industries. A trained physician and scientist, Dr. Lederman has been instrumental in leading Tonix’s strategic direction and advancing its pipeline of innovative therapeutics. He has a strong background in immunology and infectious diseases, with numerous contributions to medical research and drug development. Dr. Lederman earned his MD from Columbia University, where he also served as an Associate Professor.

Dr. Gregory Sullivan is the Chief Medical Officer of Tonix Pharmaceuticals, where he oversees the clinical development and regulatory strategy for the company’s therapeutic programs. With extensive experience in psychiatry and CNS disorders, Dr. Sullivan plays a key role in guiding Tonix’s clinical trials and ensuring the scientific rigor of its development efforts. Before joining Tonix, Dr. Sullivan had a distinguished career in academic medicine and clinical research. He holds an MD from the University of California, San Francisco, and has published widely on topics related to psychiatry and neurological disorders.

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), closed Monday's trading session at $30.51, up 32.4794%, on 135,180 volume. The average volume for the last 3 months is 1,952,584 and the stock's 52-week low/high is $6.76/$1146.0064.

Recent News

• Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) - InvestorNewsBreaks - Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Advances Fibromyalgia Drug Without Advisory Committee Review
• InvestorNewsBreaks - Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Reports Q4, Full-Year 2024 Financial Results, Highlights Key Developments
• InvestorNewsBreaks - Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Present at 2025 BIO-Europe Spring Convention

Annovis Bio Inc. (NYSE: ANVS)

The QualityStocks Daily Newsletter would like to spotlight Annovis Bio Inc. (NYSE: ANVS).

Annovis Bio (NYSE: ANVS) , a late-stage clinical drug platform company, reported fourth quarter and full year 2024 results, highlighting major milestones in its buntanetap program for Alzheimer's and Parkinson's disease. The company completed two key trials last year, showing cognitive and motor improvements, leading to FDA clearance for a pivotal Phase 3 trial in early Alzheimer's, which began in early 2025. Annovis also expanded its patent portfolio, strengthened its leadership, and increased investor engagement. Financially, R&D expenses dropped to $20 million for the year, with net loss per share improving to $2.02 basic from $6.23 in 2023. Cash on hand rose to $10.6 million, with additional funding extending runway into Q4 2025.

To view the full press release, visit https://ibn.fm/3kSS0

Annovis Bio Inc. Overview

Annovis Bio Inc. (NYSE: ANVS) is a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as AD and PD. Annovis Bio stands out by developing a drug that targets multiple neurotoxic proteins simultaneously, aiming to restore axonal and synaptic activity. This innovative approach addresses both the cognitive decline in AD and the motor dysfunction in PD, making Annovis a unique player in the neurodegeneration space.

Lead Drug Candidate: Buntanetap

Buntanetap (formerly known as Posiphen) targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43. This multifaceted inhibition improves synaptic transmission and axonal transport, reduces neuroinflammation, and protects nerve cells from dying. Unlike monoclonal antibody therapies, buntanetap is an orally available small molecule capable of inhibiting multiple neurotoxic proteins at once, positioning it as a comprehensive solution for neurodegenerative diseases.

In a recent Phase II/III Alzheimer’s study, buntanetap demonstrated statistically significant efficacy. Patients with early AD showed a significantly higher rate of improvement in ADAS-Cog 11 scores across all treatment doses compared to placebo, with a 3.3 point improvement compared to 0.3 for placebo (p < 0.01). Plasma Tau protein levels also reduced, consistent with previous Phase II biomarker data, further validating buntanetap’s mechanism of action.

Similarly, in the recently completed Phase III study of buntanetap in patients with early PD, buntanetap significantly improved disease-related daily non-motor and motor functions in Parkinson’s patients who had a diagnosis over 3 years as well as improved cognition in all PD patients. It further underscores buntanetap’s potential as a transformative therapy.

Market Opportunity

The aging population presents a significant market opportunity, with nearly 7 million Americans currently suffering from Alzheimer’s Disease (AD), a figure projected to rise to almost 13 million by 2050​ (Alzheimer’s Association)​​ (Republican Policy Committee)​. Additionally, approximately 1.2 million people in the U.S. have Parkinson’s Disease​ (SingleCare)​.

The economic burden of Alzheimer’s is immense, with care costs expected to reach $360 billion in 2024 and escalate to nearly $1 trillion annually by 2050​​. The need for effective, comprehensive treatments like Buntanetap is more critical than ever.

Company Highlights

• Innovative Therapeutic Approach: Annovis Bio uniquely targets multiple neurotoxic proteins, aiming to restore nerve cell health and improve cognitive and motor function in AD and PD patients.
• Robust Clinical Data: Phase II/III studies show significant improvements in cognitive function and biomarker levels in early AD patients.
• Groundbreaking Clinical Insights: Recent Phase III data in Parkinson’s Disease patients demonstrates significant improvements in motor and cognitive functions.
• Upcoming Phase III Trials: Plans are underway for an 18-month Phase III trial focusing on biomarker-positive early AD patients, designed to further validate buntanetap’s disease-modifying potential.
• Capital Efficiency: Annovis Bio is capital-efficient, with zero debt and multiple global patents extending into the 2040s.

Management Team

• Maria L. Maccecchini, Ph.D. – Founder, President, CEO, and Executive Board Member, founded Annovis Bio in May 2008 with the mission to develop better therapeutics for Alzheimer’s, Parkinson’s, and other neurodegenerative diseases. She has previously been a partner and director at two angel groups, Robin Hood Ventures and MidAtlantic Angel Group, and founded Symphony Pharmaceuticals/Annovis, which was sold to Transgenomic in 2001. Her extensive experience includes roles such as General Manager at Bachem Bioscience and Head of Molecular Biology at Mallinckrodt. Dr. Maccecchini holds a Ph.D. in biochemistry from the Biocenter of Basel, with postdoctoral work at Caltech and the Roche Institute of Immunology.
• Cheng Fang, Ph.D. – Senior VP of Research and Development, is an accomplished neuroscientist with two decades of experience in neurodegenerative diseases. She has a successful track record of scientific publications and contributions, coupled with extensive pre-clinical and clinical development experience. Dr. Fang has been instrumental in advancing the understanding of neurodegenerative disease mechanisms and developing therapeutic strategies.
• Michael Christie, Ph.D. – VP of Process Chemistry, has over 40 years of experience in the pharmaceutical industry, focusing on process chemistry R&D, pilot plant production, and GMP operations. He has held senior management positions at companies such as SmithKline, Rhodia, Teva, and Cephalon, and founded a contract process R&D service company, which was later acquired by ChiRex. Dr. Christie is co-author or co-inventor on several publications and patents. He earned his BS in chemistry from the University of Michigan and his doctorate from MIT.
• Melissa Gaines – Senior VP of Clinical Operations, is an accomplished clinical research professional with over 20 years of experience across academia, contract research organizations, and pharmaceutical companies. She has proven abilities in monitoring and managing Phase I to IV clinical trials, specializing in CNS disorders and extending to a broad range of therapeutic indications. Her CNS experience spans from small Phase I and II studies to large global Phase III trials in Alzheimer’s disease, Parkinson’s disease, sleep disorders, and various psychiatric diseases in both adult and pediatric populations. In her current role, she oversees and supports all clinical project activities, driving operational success and ensuring high-quality clinical outcomes.

Annovis Bio Inc. (NYSE: ANVS), closed Monday's trading session at $1.85, up 5.7143%, on 782 volume. The average volume for the last 3 months is 387,117 and the stock's 52-week low/high is $1.525/$20.

Recent News

• Annovis Bio Inc. (NYSE: ANVS) - InvestorNewsBreaks - Annovis Bio Inc. (NYSE: ANVS) Advances Alzheimer's and Parkinson's Pipeline, Launches Pivotal Phase 3 Trial
• The Brain's 'Cleanup Crew' Could Hold the Key to Alzheimer's Treatment, Study Shows
• BioMedNewsBreaks - Annovis Bio Inc. (NYSE: ANVS) to Present at Alzheimer's & Parkinson's Drug Development Summit 

Standard Lithium Ltd. (NYSE American: SLI)

The QualityStocks Daily Newsletter would like to spotlight Standard Lithium Ltd. (NYSE American: SLI).

Standard Lithium (NYSE American: SLI) , a near-commercial lithium company, reported financial and operational results for the six-month period ended Dec. 31, 2024, highlighting key milestones toward its South West Arkansas project. The company finalized a $225 million grant from the U.S. Department of Energy to support Phase 1 construction and completed successful pilot testing with over 99% lithium recovery. With FEED and DFS nearing completion and offtake discussions underway, Standard Lithium is progressing toward a final investment decision. The company also launched the Smackover Lithium joint venture with Equinor and ended the period with $31.2 million in cash and no debt.

To view the full press release, visit https://ibn.fm/HNfcL

Standard Lithium Ltd. (NYSE American: SLI) is focused on unlocking the value of existing large-scale U.S.-based lithium brine resources that can quickly be brought into production. The Company believes new lithium production can rapidly be brought on stream by minimizing project risks at selection stage; resource, political & geographic, and regulatory & permitting; and by leveraging advances in lithium extraction technologies and processes.

The Company’s flagship project is in southern Arkansas. The more than 180,000-acre “Smackover Project” is in the most prolific and productive brine processing region in North America. Agreements with large commercial brine operators in the region will allow Standard Lithium to utilize the extensive existing infrastructure, including brine supply and disposal pipelines, water, power and a trained workforce to fast-track project development timelines.

“Arkansas produces about 9.4 billion gallons of brine per year, according to 2010-2016 average statistics reported by the Arkansas Oil & Gas Commission.”

Standard Lithium signed a binding MoU with global specialty chemicals company LANXESS Corporation and its U.S. affiliate Great Lakes Chemical Corporation with the purpose of demonstrating the commercial viability of extraction of lithium from brine (“tail brine”) that is produced as part of LANXESS’ bromine extraction business at its three Southern Arkansas facilities.

LANXESS’ land operations in Southern Arkansas encompass more than 150,000 acres, 10,000 brine leases and surface agreements and 250 miles of pipelines. LANXESS extracts the brine from its wells located throughout the area, and the brine is transported to the three Arkansas plants through a network of pipelines. The three bromine extraction plants currently employ approximately 500 people and process and reinject several hundred thousand barrels of brine per day.

Standard Lithium has developed a breakthrough rapid lithium extraction process that reduces the recovery time of extracting lithium from brine to as little as several hours vs. the current industry method that takes years. The process is also much more environmentally friendly with a significantly smaller footprint than the conventional processes. The company has a signed agreement to locate a demonstration scale lithium extraction plant inside one of LANXESS’ chemical plants in Southern Arkansas.

The Company has also signed an option agreement with NYSE-listed Tetra Technologies for the lithium rights for exploration, extraction, and possible commercial development on approximately 30,000 acres of brine leases in Southern Arkansas. The largest available land package.

Recent laboratory results of four brine samples recovered from two existing wells in Standard Lithium’s project area showed lithium concentrations ranging between 347-461 mg/L lithium, with an average of 450 mg/L lithium in one of the wells and 350 mg/L in the other. Geological modeling of the project area is complete, and a maiden resource report is on the horizon.

Market Opportunity

World demand for lithium continues to surge. The global lithium compounds market is projected to reach U.S. $5.87 billion by 2020 at a compound annual growth rate of 13.22% between 2015 and 2020. Lithium-ion batteries are the fastest growing segment of the market.

Leadership

Standard Lithium’s commitment to being a premier, innovation-driven company focused on developing and commercializing new modern processes for lithium extraction is bolstered by the leading experts that comprise the company’s Scientific Advisory Council. Each member was selected because of their experience and expertise in areas that are central to and/or complement Standard Lithium’s current development plans. Standard Lithium recently welcomed to the Council world-renowned chemist Dr. Barry Sharpless, the recipient of the 2001 Nobel Prize in Chemistry for his work on chirally catalyzed oxidation reactions.

Standard Lithium is led by a team of professionals with proven strong technical and project development skills. CEO Robert Mintak has a global network of industry contacts and is a pioneer in the rapidly evolving lithium space. COO and President Dr. Andy Robinson is an experienced geoscientist with 20+ years of experience and a PhD in Geochemistry from the University of Bristol, UK. Dr. Robinson has worked on a wide range of projects in the resource, power and energy sectors in Europe, Africa, and North and South America.

The company recently appointed Robert Cross as non-executive chairman. Cross is an engineer with 25 years of experience as a financier and company builder in the mining and oil and gas sectors. He co-founded and serves as chairman of B2Gold, a top-performing growing gold producer which is expected to achieve nearly 1 million ounces of low-cost gold production in 2018. He was also co-founder and chairman of Bankers Petroleum Ltd.; co-founder and chairman of Petrodorado Energy Ltd.; and until October 2007 was the non-executive chairman of Northern Orion Resources Inc. He also was previously the chairman and CEO of Yorkton Securities Inc., and a partner in investment banking with Gordon Capital Corp. in Toronto. Cross has an engineering degree from the University of Waterloo (1982) and received an MBA from Harvard in 1987.

Following a multi-million-dollar financing in Q1 2018, Standard Lithium is well-positioned to meet its upcoming milestones including two maiden resource reports and the launch of its breakthrough rapid lithium extraction technology.

Standard Lithium Ltd. (NYSE American: SLI), closed Monday's trading session at $1.31, up 0.7692308%, on 320 volume. The average volume for the last 3 months is 1,293,994 and the stock's 52-week low/high is $1.05/$2.64.

Recent News

• Standard Lithium Ltd. (NYSE American: SLI) - MiningNewsBreaks - Standard Lithium Ltd. (NYSE American: SLI) Advances Toward Final Investment Decision With $225M DOE Grant
• InvestorNewsBreaks - Standard Lithium Ltd. (NYSE American: SLI) Appoints Karen G. Narwold to Board of Directors
• GreenEnergyBreaks - Standard Lithium Ltd. (NYSE American: SLI) Achieves Key Milestone in Smackover Lithium JV DLE Process 

HealthLynked Corp. (OTCQB: HLYK)

The QualityStocks Daily Newsletter would like to spotlightFathom HealthLynked Corp. (OTCQB: HLYK) .

HealthLynked (OTCQB: HLYK) , a global healthcare network focused on improving patient care, announced updates to its in-office online appointment booking system and enhancements to its ARi voice assistant. New scheduling features include next-available or specific-day requests, flexible time-of-day preferences, and the ability to submit provider reviews without logging in. Upgrades to ARi include improved background noise filtering and smarter response detection, designed to boost reliability and user experience. These innovations aim to streamline scheduling and enhance communication between patients and healthcare providers.

To view the full press release, visit https://ibn.fm/ECDUv

HealthLynked Corp. (OTCQB: HLYK) is at the forefront of a transformative movement in healthcare, utilizing its extensive collection of health data to improve care for all. With a commitment to leveraging its advanced technology platforms, HealthLynked employs a sophisticated, cloud-based network that serves as a comprehensive repository for personal health data. This system not only simplifies the management and archiving of medical records but also enables the application of AI to deliver personalized healthcare insights. Through deep analysis of this data, HealthLynked’s AI capabilities help identify the root causes of diseases, tailor healthcare solutions to individual needs, and accelerate medical discoveries.

In addition to these capabilities, HealthLynked provides a user-friendly platform for booking healthcare appointments, similar to how OpenTable operates for restaurant reservations. This feature allows patients to conveniently book appointments with healthcare providers across the country, including options for telemedicine consultations, enhancing accessibility and efficiency in healthcare service delivery.

Strategically headquartered in Naples, Florida, HealthLynked operates through three primary divisions: Health Services, Digital Healthcare, and Medical Distribution. Each division supports the company’s mission to revolutionize patient care and health management. Positioned as a potential leader in healthcare AI, HealthLynked is dedicated to shaping the future of the industry over the next 20 years, driving significant advancements in healthcare accessibility and effectiveness through innovation and technology.

Strategic Initiatives and Operational Highlights

The company’s commitment to enhancing global health is evident in its dual goals: transforming healthcare through advanced technology and creating a patient-centric network that accelerates medical discoveries and the development of disease cures.

HealthLynked’s intellectual property portfolio is robust and strategically developed to enhance healthcare delivery and management. In March 2023, HealthLynked was granted a patent for a groundbreaking healthcare-specific wireless access point, known as the “Patient Access Hub.” This technology significantly improves the efficiency of healthcare practices by enabling real-time monitoring of patient flow within facilities. It intelligently determines patients waiting in exam rooms and calculates wait times, alongside other critical practice metrics. This system not only enhances patient experience by reducing unnecessary wait times but also optimizes resource allocation within healthcare settings.

Additionally, in October 2023, HealthLynked filed a patent application for its advanced AI program, ARI (Augmented Real-time Interface). ARI acts as a virtual doctor for patients, capable of performing medical intake, booking appointments, and providing personalized medical recommendations based on a patient’s medical history. By integrating these tasks, ARI streamlines the healthcare process, reducing the administrative burden on healthcare providers and ensuring that patients receive timely and tailored healthcare advice. This AI-driven interface enhances the accessibility and personalization of healthcare, embodying HealthLynked’s commitment to leveraging technology for better health outcomes. The company recently launched HealthLynked 3.2.0, an advanced version of its application, incorporating telemedicine, AI-driven personal healthcare guidance, and remote patient monitoring – setting a new standard in healthcare technology.

Market Position and Future Outlook

According to Facts and Figures Research, a research and consulting firm, the global market for patient-centric healthcare applications is projected to reach $41.6 billion by 2030, growing at a CAGR of 18.77% from 2022. HealthLynked’s offerings align perfectly with this expansive market opportunity, especially with increasing demands for digital health solutions and data management in healthcare.

HealthLynked’s strategic direction, spearheaded by its seasoned management team, is designed to leverage these market dynamics, enhancing patient engagement and healthcare efficiency on a global scale.

Management Team

Michael T. Dent, M.D., Founder, CEO, and Chairman, brings extensive experience from his foundational role at NeoGenomics and leadership in various healthcare and technology sector companies.

David Rosal, CFO, with previous senior roles at Teradata and McDonald’s Corporation, brings a wealth of expertise in financial and business integration strategies essential for growth and operational efficiency.

Chris Hall, CTO, with a strong background in global technology development from his time at Siemens and several patents to his name, is instrumental in driving the innovation and technological advancement at HealthLynked.

Bill Crupi, Operations Manager, has a proven track record in streamlining operations and enhancing productivity across multiple sectors within the healthcare industry. His expertise is crucial in maintaining the operational excellence that HealthLynked is known for.

Michael Paisan, Director of Investor Relations, leverages his extensive experience in finance and communications to enhance HealthLynked’s relationships with investors and stakeholders, ensuring transparent and effective communication of the company’s value and growth strategy.

Gagan Babber, Manager of Software Development, oversees the HealthLynked development teams based in the U.S. and India. With a robust background in engineering and software development, he plays a critical role in guiding the technological direction of HealthLynked’s products. His expertise in developing scalable, innovative software solutions is essential for driving the company’s technical initiatives forward and ensuring that HealthLynked stays at the forefront of digital healthcare technology.

HealthLynked Corp. (OTCQB: HLYK), closed Monday's trading session at $0.035, up 1.8923%, on 88,500 volume. The average volume for the last 3 months is 361,730 and the stock's 52-week low/high is $0.0031/$0.0981.

Recent News

• HealthLynked Corp. (OTCQB: HLYK) - InvestorNewsBreaks - HealthLynked Corp. Enhances Booking Platform and ARi Voice Assistant
• Why it is Crucial to Prepare Healthcare Data for Use in AI Models
• InvestorNewsBreaks - HealthLynked Corp. Highlights 2024 Achievements, Sets Vision for Future Growth

Aditxt Inc. (NASDAQ: ADTX)

The QualityStocks Daily Newsletter would like to spotlight Aditxt Inc. (NASDAQ: ADTX).

Aditxt (NASDAQ: ADTX) announced that its subsidiary, Pearsanta, Inc., has acquired key patents for adductomics-based DNA damage detection in a $1 million stock transaction. The move expands Pearsanta's capabilities in early cancer risk assessment, complementing its existing Mitomic® Technology. The acquired technology detects DNA adducts—early markers of carcinogen exposure—allowing for potential cancer prevention strategies before permanent mutations develop. Pearsanta plans to advance clinical validation and regulatory pathways over the next two to three years, aiming to commercialize the diagnostics through CLIA/CAP-certified labs.

To view the full press release, visit https://ibn.fm/lbefw

Aditxt Inc. (NASDAQ: ADTX) is a biotech innovation company developing technologies focused on mapping and reprogramming the immune system. Aditxt’s immune mapping technologies are designed to provide a personalized immune profile. Aditxt’s immune reprogramming technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases, and allergies.

As further discussed below, the company’s first commercial product is an immune mapping technology, AditxtScore™, which is designed to provide a personalized profile of the immune system.

The company’s preclinical immune reprogramming technology, Apoptotic DNA Immunotherapy™ (“ADi™”), aims to retrain the immune system to induce tolerance, with the goal of addressing vast unmet needs in transplanted organ rejection, autoimmune diseases, and allergies. The company is developing specific ADi™ products for psoriasis, type 1 diabetes, and skin grafting.

Headquartered in Richmond, Virginia, Aditxt also operates locations in Silicon Valley and New York.

AditxtScore™

AditxtScore™ is a proprietary platform designed to provide a personalized, comprehensive profile of an individual’s immune system. The underlying technology, licensed from Stanford University through an exclusive worldwide agreement, offers a highly sensitive and accurate method of detecting and quantifying cellular responses, allowing greater specificity, quantification, and amplification of both clinical and commercial opportunities.

The company’s first commercial application of the platform, AditxtScore™ for COVID-19, delivers timely reports on vulnerability and immune status relating to SARS-CoV-2 and its known variants, giving consumers and physicians the data needed to make informed health decisions. Potential future applications will offer early detection of an array of conditions, including diabetes, cardio-metabolic maladies and hormonal imbalances.

Aditxt’s AditxtScore™ immune monitoring center in Richmond, Virginia, is operational and designed to support the anticipated increased demand for AditxtScore™ as well as related products and services. The company is currently scaling its capabilities at this location, with a goal of processing up to 10 million immune system tests/reports annually.

ADi™

ADi™ is Aditxt’s immune reprogramming platform addressing disease-causing immune responses while maintaining the immune system’s ability to combat pathogenic infection. The company is commercializing a nucleic acid-based technology called Apoptotic DNA Immunotherapy™ (ADi™) which utilizes a novel approach that mimics the way our bodies naturally induce tolerance to our own tissues (therapeutically induced immune tolerance). Aditxt believes its ADi™ technology platform can be engineered to address a wide variety of indications.

Aditxt is currently developing ADi™ products for psoriasis, type 1 diabetes and skin grafting.

Currently, immuno-tolerance is achievable through chimerism and cell-based therapy, but there is a clinical need for a more practical and cost-effective approach which:

• Can be made into a product
• Does not require additional hospitalization
• Is simple to produce and ship

Preclinical studies have demonstrated that ADi™ treatment significantly and substantially prolongs graft survival, in addition to successfully “reversing” other established immune-mediated inflammatory processes. ADi™ treatment is not expected to require hospitalization, instead being delivered as an injection in minute amounts into the skin.

IP Portfolio

Both AditxtScore™ and ADi™ are supported by a strong IP portfolio.

AditxtScore™, built upon initial technology invented, licensed from and used at Stanford University, is protected by U.S. patents encompassing methods, systems, and kits for detection and measurement of specific immune responses.

ADi™ technology is protected by seven patent families, including:

• 8 U.S. patents
• 4 pending U.S. patent applications
• 86 foreign patents and 14 pending foreign patent applications spanning the EU, Australia, Canada, Japan, China, India and Hong Kong

These patents are broadly categorized into three groups:

• Autoimmune diseases and Type 1 Diabetes
• Organ transplantation and a method of producing plasmid DNA to prevent immune activation
• Composition of matter for a tolerance delivery system for antigens of interest

Aditxt also possesses and/or in-licenses substantial know-how and trade secrets relating to the development and commercialization of its product candidates, including related manufacturing processes and technologies.

Market Overview

The potential market opportunities presented by immune monitoring and reprogramming are extensive, particularly as Aditxt continues to evaluate additional applications for the platforms.

The company’s initial focus on organ transplantation and related autoimmune response provides some insight into the potential of its approach. According to BCC Research, the global organ and tissue transplantation and alternatives market is on course to reach $120.3 billion by 2024, recording a CAGR of 7.4% from 2019. Industry data suggest that approximately 50% of all transplanted organs are rejected within 10-12 years, further highlighting the critical need for a practical, cost-effective solution to harmful autoimmune responses.

Through its focus on the COVID-19 testing market with AditxtScore™, Aditxt demonstrated the wide-ranging potential of its portfolio. Fortune Business Insights estimated the global COVID-19 diagnostics market at $48.64 billion for 2022. While demand for COVID-19 diagnostics is expected to lessen in the coming years, Aditxt will be uniquely positioned to leverage its existing infrastructure stemming from these operations as the company works to advance broader applications for the AditxtScore™ platform.

Leadership Team

Amro Albanna is the Co-Founder, Chairman, and CEO of Aditxt. He has founded multiple startups to commercialize innovations in various industries, including healthcare, enterprise software, telecommunications, nano technology, consumer health, and biotech. Mr. Albanna has led numerous M&A and going-public transactions as a founder, co-founder, and senior executive.

Shahrokh Shabahang, D.D.S., MS, Ph.D., is the company’s Co-Founder, Chief Innovation Officer, and a member of its board. He brings to the team more than 20 years of experience in developing and commercializing life science technologies focused on product and clinical development in the fields of microbiology and immunology.

Corinne Pankovcin, CPA, MBA, is the President of Aditxt. Prior to joining Aditxt, Ms. Pankovcin served as CFO for several world class organizations, including Business Development Corporation of America, Blackrock Kelso Capital and AIG Capital Partners. In these roles, Ms. Pankovcin was responsible for executing portfolio investments and managing significant M&A transactions.

Thomas Farley is the Chief Financial Officer of Aditxt. From December 2015 to June 2020, Mr. Farley was the Controller and Treasurer of Business Development Corporation of America (“BDCA”), a publicly listed business development company. Prior thereto, from January 2011 to August 2015, Mr. Farley was the Senior Controller of Blackrock Capital Investment Corporation (NASDAQ: BKCC). Prior to joining BlackRock Capital Investment Corporation, Mr. Farley was a Senior Controller for PineBridge Investments Emerging Markets practice. Mr. Farley was also an Accounting Manager for Bessemer Venture Partners prior to his tenue at PineBridge. Mr. Farley began his career with PricewaterhouseCoopers LLP, from 1996 to 2001. Mr. Farley earned his B.S. in Accounting from Long Island University and is a Certified Public Accountant.

Rowena Albanna is the company’s Chief Operating Officer. Ms. Albanna has over two decades of experience in senior leadership roles for both technology startups and public companies. Ms. Albanna’s experience spans a wide variety of industries, including biotechnology, insect control, nanotechnology, consumer electronics, financials, telecommunications, e-commerce, online marketing, medical, and defense.

Matthew Shatzkes is the Chief Legal Officer and General Counsel of Aditxt. As a former partner at an AM Law 50 law firm, Mr. Shatzkes advised a wide variety of healthcare related entities, including biotech companies, on corporate, regulatory, and strategic business matters. Mr. Shatzkes will oversee all aspects of the legal functions at Aditxt, including, providing advice and counsel on governance, regulatory matters, strategic alliances, mergers and acquisitions, and commercial transactions.

Aditxt Inc. (NASDAQ: ADTX), closed Monday's trading session at $7.17, off by 25.5452%, on 16,597 volume. The average volume for the last 3 months is 6,914,638 and the stock's 52-week low/high is $4.11/$54500.

Recent News

• Aditxt Inc. (NASDAQ: ADTX) - InvestorNewsBreaks - Aditxt Inc. (NASDAQ: ADTX) Subsidiary Pearsanta Acquires Patents for DNA Damage Detection in Cancer Prevention
• InvestorNewsBreaks - Aditxt Inc. (NASDAQ: ADTX) Explores IPO for Pearsanta to Advance Early Cancer Detection
• InvestorNewsBreaks - Aditxt Inc. (NASDAQ: ADTX) Subsidiary Advances ADI-100 Gene Therapy Toward Human Trials

Datavault AI Inc. (NASDAQ: DVLT)

The QualityStocks Daily Newsletter would like to spotlight Datavault AI Inc. (NASDAQ: DVLT).

Datavault AI (NASDAQ: DVLT) , a leader in AI-powered data valuation and monetization, announced its inclusion in IBM's Partner Plus program, joining a global network of 500 partners. The company will integrate IBM watsonx tools into its AI agents—Data Vault Bank®, DataScore® and DataValue®—to advance secure, compliant enterprise data monetization. Datavault AI also completed integration with identity partner CLEAR and expanded its strategic alliance with NYIAX. These developments position the company at the forefront of AI-driven financial modeling and tokenization across highly regulated sectors.

To view the full press release, visit https://ibn.fm/rDXQy

Datavault AI Inc. (NASDAQ: DVLT) is a pioneering leader in immersive, wireless sound technology, providing cutting-edge audio solutions for intelligent devices and next-generation home entertainment systems. The company collaborates with top consumer electronics (CE) brands and manufacturers, including industry giants like Harman International (a division of Samsung), LG, Hisense, TCL, Bang & Olufsen, and Platin Audio. WiSA Technologies delivers exceptional wireless sound experiences for high-definition content, including movies, music, sports, gaming, and esports, thereby enhancing the overall consumer experience in home entertainment.

As a founding member of WiSA™ (the Wireless Speaker and Audio Association), WiSA Technologies plays a critical role in defining wireless audio interoperability standards, ensuring seamless integration across devices and platforms. The company actively works with leading consumer electronics companies, technology providers, retailers, and ecosystem partners to promote and market spatial audio technologies, underscoring its commitment to advancing the future of audio and making high-quality, immersive sound accessible to a broader audience.

Headquartered in Beaverton, Oregon, WiSA Technologies extends its global reach with sales teams strategically located in Taiwan, China, Japan, Korea, and California. This international presence allows the company to effectively serve a diverse customer base and maintain strong relationships with key partners worldwide. By continuously innovating and setting new benchmarks in wireless audio, WiSA Technologies is well-positioned to remain at the forefront of the evolving home entertainment landscape.

The WiSA Association

The WiSA® Association, a wholly owned subsidiary of WiSA Technologies, is dedicated to promoting and standardizing spatial audio solutions for home entertainment, ensuring that immersive audio experiences are accessible to everyone. In collaboration with leading consumer electronics companies, technology providers, retailers, and ecosystem partners, the association works to advance wireless audio technology across various devices, making high-quality sound an integral part of modern home entertainment systems. As a key player in the industry, WiSA LLC, also known as the Wireless Speaker and Audio Association, is instrumental in fostering the adoption and integration of cutting-edge audio technologies.

Recently, the WiSA Association significantly expanded its influence by executing licensing agreements with leading HDTV brands, covering 43% of the HDTV market that uses the Android operating system, the most widely used OS in the market. By focusing on Android-based HDTVs and collaborating with speaker manufacturers, WiSA is actively building an ecosystem of WiSA E-enabled speaker systems, mirroring the success of its earlier WiSA HT technology. This strategic initiative, combined with WiSA E’s compatibility with multiple HDTV SoC providers and support for spatial audio formats like Dolby Atmos FlexConnect, positions the association at the forefront of transforming home audio experiences, driving widespread adoption across the home entertainment landscape.

Market Opportunity

From an investment perspective, WiSA Technologies Inc. is strategically positioned to capitalize on the growing demand for wireless and immersive audio experiences as consumer preferences shift toward high-definition home entertainment systems. As streaming services, gaming, and smart home technologies continue to expand, the need for seamless, high-quality audio solutions is becoming increasingly critical. WiSA Technologies, with its innovative wireless sound technology and strong partnerships with leading consumer electronics brands, is well-placed to capture a significant share of this expanding market, particularly as more consumers seek to enhance their home entertainment experiences.

Moreover, the company’s focus on setting industry standards through the WiSA Association further solidifies its role as a key player in the evolving audio landscape. By driving the adoption of wireless audio interoperability standards, WiSA Technologies not only ensures broad compatibility across devices but also positions itself as a leader in the market, capable of influencing future trends and technologies. This proactive approach, combined with its established global presence and collaborations with top-tier brands, provides WiSA Technologies with a strong foundation for sustained growth, making it an attractive opportunity for investors looking to gain exposure to the burgeoning home entertainment and smart audio sectors.

Leadership Team

Brett Moyer is the Chief Executive Officer, President, and Chairman of WiSA Technologies, Inc., and a founding member of the company. He has served in these leadership roles since August 2010. Prior to this, Mr. Moyer was the president and CEO of Focus Enhancements, Inc., where he oversaw the development and marketing of proprietary video technology. He has a rich background in consumer electronics, having held key positions at Zenith Electronics Inc., including Vice President and General Manager of its Commercial Products Division. Mr. Moyer also serves on the board of directors of Alliant International University and has previously served on the boards of HotChalk, Inc., and NeoMagic Corporation. He holds a Bachelor of Arts in Economics from Beloit College and an MBA in Finance and Accounting from Thunderbird School of Global Management.

Gary Williams is the Chief Accounting Officer and Vice President of Finance at WiSA Technologies, Inc., roles he has held since September 2019 and the company’s founding in August 2010, respectively. He previously served as the company’s Chief Financial Officer and Secretary until 2019. Mr. Williams has extensive experience in finance, having served as CFO of Quantum3D, Inc., and in similar roles at Focus Enhancements Inc. and Videonics Inc. He began his career in public accounting with Coopers & Lybrand LLP. Mr. Williams is a certified public accountant (inactive) and holds a bachelor’s degree in business administration with an emphasis in accounting from San Diego State University.

Datavault AI Inc. (NASDAQ: DVLT), closed Monday's trading session at $0.9537, off by 11.6944%, on 35,813 volume. The average volume for the last 3 months is 1,006,565 and the stock's 52-week low/high is $0.693/$10.95.

Recent News

• Datavault AI Inc. (NASDAQ: DVLT) - AINewsBreaks - Datavault AI Inc. (NASDAQ: DVLT) Partners with Realtek to Showcase WiSA E Tech at Convergence India Expo 
• InvestorNewsBreaks - Datavault AI Inc. (NASDAQ: DVLT) Announces WiSA SoundSend Certification for Optoma HCPro-4400 Projector
• InvestorNewsBreaks - WiSA Technologies Inc. (NASDAQ: WISA) Rebrands as Datavault AI Inc. (NASDAQ: DVLT)

GivBux Inc. (OTC: GBUX)

The QualityStocks Daily Newsletter would like to spotlightFathom GivBux Inc. (OTC: GBUX) .

GivBux Inc. (OTC: GBUX) is a publicly traded super app and charitable giving platform. The company is creating a sharing economic community of brands and consumers in which consumers have an easier and more convenient way to shop and buy, merchants have a more efficient and profitable way to advertise, and charities receive built-in contributions from the community’s transactions.

The GivBux Super App revolutionizes shopping by offering a user-friendly tool to make purchases swiftly at over 100 national retailers, along with an expanding roster of local merchants. Users earn cash back on every purchase, a portion of which can be directed toward a charity of their choice, embodying GivBux’s commitment to giving back. Additionally, the app is evolving to include numerous functionalities like social networking, e-commerce, banking, messaging, food delivery and transportation, following the super app model.

GivBux is forging a new path in charitable giving, with aspirations to build the largest community of givers in the United States, and eventually globally. The company believes it is uniquely positioned to make a major contribution to society by overlapping the worlds of commerce and philanthropy.

The GivBux Super App is currently available for free on the Google Play Store and the Apple App Store.

The company is headquartered in Newport Beach, California.

Products

The company, through wholly owned subsidiary GivBux Global Partners Inc., is engaged in the fintech mobile wallet sector, specifically as a point-of-sale payment system by means of a consumer mobile wallet. GivBux uses smartphone technology to bridge consumers and merchants together without the need for traditional plastic cards or paper cash.

The GivBux mobile app has been designed to store, send and receive funds; donate; and make real-time purchases at top retail brands, restaurants and other venues. The brands benefit, because they are empowered with a data-rich marketing tool to reach and retain consumers through their mobile phones.

With GivBux, recipients can use funds instantly by paying with their mobile phones at thousands of locations. GivBux rewards all users for using the app every time they make a purchase and every time their friends, friends of friends and stranger friends make purchases with the GivBux mobile wallet. These rewards can be redeemed for cash to pay at participating retail stores, restaurants, cinemas, entertainment venues and more.

Moreover, GivBux allows users to contribute to a charity or worthy cause of their choice. To encourage giving and recommendations, a trending ‘Top 10 List’ of all charities will be generated and displayed on the mobile wallet based on ongoing contributions by GivBux users.

Market Opportunity

A report from Future Market Insights, a New York-based market research organization, estimated the worldwide mobile wallet market at $9.5 billion in 2023. The report projects that in 2024 the industry is likely to reach a valuation of $11.9 billion, and, by 2034, the mobile wallet market is forecast to grow to a value of $138.5 billion, achieving a CAGR of 27.8% over the forecast period.

Key market growth drivers include payment convenience, transaction security and continuing technological innovation. The report points out that mobile wallet payments are widely accepted worldwide, fueled by a rise in digital transactions and a growing use of mobile phones for simple and effective payment options. Innovations like blockchain integration, contactless payments and artificial intelligence are improving functionality and user experience while staying ahead of rapidly evolving digital payment trends, according to the report.

Management Team

Umesh Singh is President and Director at GivBux. He is a Certified Professional Accountant (Canada) with more than 25 years of experience in accounting and finance. He began his career at PwC before joining Hayes Stuart Little & Company (now Grant Thornton), where he was Senior Accountant-Manager and later Partner. Prior to being named GivBux president, he was a member of the GivBux Advisory Board for more than three years.

Michael Arnkvarn is Vice President of International Business Development at GivBux. He has over 30 years of experience in management, sales and marketing. He managed several medium and large agribusiness and environmental businesses before founding Collagenna Skin Care Products, a natural health products and cosmetics company, in 2004. He has been CEO of multiple public small-cap companies and co-founder of a start-up cannabis company that eventually sold for more than $800 million.

GivBux Inc. (OTC: GBUX), closed Monday's trading session at $5.1, up 53.6145%, on 63,861 volume. The average volume for the last 3 months is 17,810 and the stock's 52-week low/high is $0.2001/$10.05.

Recent News

• GivBux Inc. (OTC: GBUX) - TechMediaBreaks - GivBux Inc. (GBUX) Approves Special Dividend Warrant Issuance
• EU Technology Consortium Commits to Tackling 6G ESG Concerns
• InvestorNewsBreaks - GivBux Inc. (GBUX) Enhances Super App With UI/UX Upgrades and Cloud Biometrics